These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36539562)

  • 1. Evaluation of the gene encoding carnitine transporter (OCTN2/SLC22A5) expression in human breast cancer and its association with clinicopathological characteristics.
    Dinarvand N; Karimi F; Azizi R; Rastaghi S; Sheikhi A; Pourfarzam M
    Mol Biol Rep; 2023 Mar; 50(3):2061-2066. PubMed ID: 36539562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activity and surface presence of organic cation/carnitine transporter OCTN2 (SLC22A5) in breast cancer cells depends on AKT kinase.
    Papierniak-Wyglądała A; Lamch W; Jurewicz E; Nałęcz KA
    Arch Biochem Biophys; 2023 Jul; 742():109616. PubMed ID: 37187422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLC22A5 (OCTN2) Carnitine Transporter-Indispensable for Cell Metabolism, a Jekyll and Hyde of Human Cancer.
    Juraszek B; Nałęcz KA
    Molecules; 2019 Dec; 25(1):. PubMed ID: 31861504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioma cells survival depends both on fatty acid oxidation and on functional carnitine transport by SLC22A5.
    Juraszek B; Czarnecka-Herok J; Nałęcz KA
    J Neurochem; 2021 Mar; 156(5):642-657. PubMed ID: 32654140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carnitine transport and fatty acid oxidation.
    Longo N; Frigeni M; Pasquali M
    Biochim Biophys Acta; 2016 Oct; 1863(10):2422-35. PubMed ID: 26828774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE).
    Wang C; Uray IP; Mazumdar A; Mayer JA; Brown PH
    Breast Cancer Res Treat; 2012 Jul; 134(1):101-15. PubMed ID: 22212555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carnitine deficiency in OCTN2-/- newborn mice leads to a severe gut and immune phenotype with widespread atrophy, apoptosis and a pro-inflammatory response.
    Sonne S; Shekhawat PS; Matern D; Ganapathy V; Ignatowicz L
    PLoS One; 2012; 7(10):e47729. PubMed ID: 23112839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal Plasma l-Carnitine Reduction During Pregnancy Is Mainly Attributed to OCTN2-Mediated Placental Uptake and Does Not Result in Maternal Hepatic Fatty Acid
    Bai M; Zeng Q; Chen Y; Chen M; Li P; Ma Z; Sun D; Zhou H; Zheng C; Zeng S; Jiang H
    Drug Metab Dispos; 2019 Jun; 47(6):582-591. PubMed ID: 30918014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycosylation of the OCTN2 carnitine transporter: study of natural mutations identified in patients with primary carnitine deficiency.
    Filippo CA; Ardon O; Longo N
    Biochim Biophys Acta; 2011 Mar; 1812(3):312-20. PubMed ID: 21126579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional genomics of OCTN2 variants informs protein-specific variant effect predictor for Carnitine Transporter Deficiency.
    Koleske ML; McInnes G; Brown JEH; Thomas N; Hutchinson K; Chin MY; Koehl A; Arkin MR; Schlessinger A; Gallagher RC; Song YS; Altman RB; Giacomini KM
    Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2210247119. PubMed ID: 36343260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Carnitine - mitochondria and beyond].
    Nałęcz KA; Nałęcz MJ
    Postepy Biochem; 2016; 62(2):85-93. PubMed ID: 28132459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of Octn2 transporter (SLC22A5) by peroxisome proliferator activated receptor alpha.
    Maeda T; Wakasawa T; Funabashi M; Fukushi A; Fujita M; Motojima K; Tamai I
    Biol Pharm Bull; 2008 Jun; 31(6):1230-6. PubMed ID: 18520060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional expression of organic cation/carnitine transporter 2 (OCTN2/SLC22A5) in human brain capillary endothelial cell line hCMEC/D3, a human blood-brain barrier model.
    Okura T; Kato S; Deguchi Y
    Drug Metab Pharmacokinet; 2014; 29(1):69-74. PubMed ID: 23877104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caveolin-1--a novel interacting partner of organic cation/carnitine transporter (Octn2): effect of protein kinase C on this interaction in rat astrocytes.
    Czeredys M; Samluk Ł; Michalec K; Tułodziecka K; Skowronek K; Nałęcz KA
    PLoS One; 2013; 8(12):e82105. PubMed ID: 24349196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in drug delivery via the organic cation/carnitine transporter 2 (OCTN2/SLC22A5).
    Kou L; Sun R; Ganapathy V; Yao Q; Chen R
    Expert Opin Ther Targets; 2018 Aug; 22(8):715-726. PubMed ID: 30016594
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Fink MA; Paland H; Herzog S; Grube M; Vogelgesang S; Weitmann K; Bialke A; Hoffmann W; Rauch BH; Schroeder HWS; Bien-Möller S
    Clin Cancer Res; 2019 May; 25(9):2874-2886. PubMed ID: 30670496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5).
    Tahara H; Yee SW; Urban TJ; Hesselson S; Castro RA; Kawamoto M; Stryke D; Johns SJ; Ferrin TE; Kwok PY; Giacomini KM
    J Pharmacol Exp Ther; 2009 Apr; 329(1):262-71. PubMed ID: 19141711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Embryonic lethality in mice due to carnitine transporter OCTN2 defect and placental carnitine deficiency.
    Shekhawat PS; Sonne S; Matern D; Ganapathy V
    Placenta; 2018 Sep; 69():71-73. PubMed ID: 30213487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carnitine content and expression of mitochondrial beta-oxidation enzymes in placentas of wild-type (OCTN2(+/+)) and OCTN2 Null (OCTN2(-/-)) Mice.
    Shekhawat PS; Yang HS; Bennett MJ; Carter AL; Matern D; Tamai I; Ganapathy V
    Pediatr Res; 2004 Sep; 56(3):323-8. PubMed ID: 15240869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the organic cation/carnitine transporter family (Octn1,-2 and-3) in mdx muscle and heart: Implications for early carnitine therapy in Duchenne muscular dystrophy to improve cellular carnitine homeostasis.
    Lamhonwah AM; Tein I
    Clin Chim Acta; 2020 Jun; 505():92-97. PubMed ID: 32070725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.